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A somatic ell mutant has been isolated which IS resistant to killing and growth inhibition by mevmolm, 
a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase The resistance 
phenotype IS dominant with respect to the wild-type cell and can largely be ascribed to a 67-fold lowering 
of the KM for HMG-CoA We thus conclude that mevmolm resistance an be utilized to obtain a genetic 
marker for the structural gene ncoding HMH-CoA reductase 
HMG-CoA reductase Genetlc marker Mevmolin resrstance 
1. INTRODUCTION 
Studies on the enzymes of mevalonate biosyn- 
thesis m cultured mammalian cells and m whole 
animal liver [l] have demonstrated that these en- 
zymes are regulated by a variety of intracellular 
processes [2,3]. Intensive analysis of the best 
characterized enzyme involved m these reactions, 
HMG-CoA reductase [4], has shown that this third 
step m mevalonate biosynthesis is regulated by ex- 
ogenous sterols and mevalonate by mechamsms in- 
volving regulation of enzyme biosynthesis [5] (both 
transcription [6] and translation [7]), enzyme 
degradation [7-91, and catalytic efficiency, par- 
ticularly by mechanisms mvolvmg reversible 
phosphorylation [lo]. Other more preliminary 
studies suggest that the second enzyme of 
mevalonate biosynthesis HMG-CoA synthase is 
coordinately regulated [ 11,121 with HMG-CoA 
reductase at the level of enzyme biosynthesis. 
Because of the capability of applying nutritional 
criteria for the selection of mammalian cell 
variants m mevalonate and sterol biosynthesis, the 
techniques of somatic cell genetics have been suc- 
cessfully applied to the mevalonate biosynthetic 
enzymes and have yielded a number of significant 
results. Currently, there exist somatic cell mutants 
in mevalonate biosynthesis with both constitutive 
[ 13,141 and repressed expression [ 151 of these en- 
zymes; mutants that exhibit dramatic over expres- 
sion of HMG-CoA reductase [16,17] and 
mevalonate auxotrophs missing either HMG-CoA 
synthase [18] or HMG-CoA reductase [19] ac- 
tivities. The latter mutants can be particularly 
useful for studies of gene expression and 
chromosomal and fme structure mappmg by 
means of gene transfer and somatic cell hybridiza- 
tion techniques. However, particularly with regard 
to HMG-CoA reductase, the complexity of the 
regulatory process has made it hard to select for 
structural gene mutants as opposed to regulatory 
mutations. Indeed, two mevalonate auxotrophs, 
which have been characterized as being defective m 
HMG-CoA reductase activity, appear to be defec- 
tive in regulatory genes for expression of the en- 
zyme rather than m the enzyme itself [15,19]. In 
order to apply the techmques of somatic cell 
genetics to the HMG-CoA reductase gene we have 
sought a method that would select directly for 
structural gene mutations m HMG-CoA reductase. 
Here we describe the selection of a somatic cell mu- 
tant generated by ethylmethane sulfonate 
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mutagenesis which is highly resistant o killmg by 
mevmolm [20], a compound which is a competitrve 
inhibitor of HMG-CoA reductase. Evidence is 
presented that suggests that this mutant acquires 
resistance to mevmolin, m part, by an alteration m 
HMG-CoA reductase itself and, hence, m the 
structural gene encoding that enzyme. 
2. MATERIALS AND METHODS 
The CHO-Kl (pro-) parent strain [21] and the 
CHL (AT-) [13] line have been described. Cells 
were routinely grown in Ham’s F12 [22] sup- 
plemented with 8% neonatal calf serum. 
Dominance tests by somatic cell hybridrzation were 
described m [13]. 
For isolation of mevinolin resistant mutants, 1 x 
lo8 CHO-Kl cells (5 x 106/150 mm petri dish) 
were mutagemzed by treatment with 0 4 &ml 
ethylmethanesulfonate for 18 h. The medium was 
then changed to fresh growth medium and the cells 
incubated for an additional 24 h to permit expres- 
sion of an altered enzyme Mevmolin (10 pg/ml) 
was then added to the cultures and the cells m- 
cubated with regular medium changes until a visi- 
ble clone appeared (2 weeks). The MXl clone was 
the only mevinohn resistant clone observed m 3 
such attempts. Mevmohn was a gift of Dr A. 
Alberts, of Merck Pharmaceuticals. 
2.1 Enzyme assays 
Assays for HMG-CoA synthase [181 and HMG- 
CoA reductase have been described in [13] Cells 
were incubated in F12 medium supplemented with 
2% organic solvent dehpidized serum (DIPE-2) 
prepared as described m [23] or 5% fetal calf 
serum prior to enzyme assays. Regulation of these 
enzymes by the mhrbrtory sterol, 25hydroxycho- 
lesterol, was tested accordmg to [ 181. KM and KI 
determinations were by regression to the Eadie- 
Hofstee equation. Mevmolm concentrations used 
were 2 x 10m9 and lo-’ M 
2.2 HMG-CoA determrnatlons 
Unreacted HMG-CoA was recovered from assay 
mixes by direct application of ahquots of these 
mixes to silica gel thin-layer plastic-backed 
chromatography plates. A companion standard of 
radroactrve HMG-CoA that was incubated in assay 
buffer without any added cell extract was utilized 
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to correct for both loss and rmpuritres m the mitral 
HMG-CoA sample. These TLC plates (Polygram 
SiLG, Brmkmann Inst., Westbury, NY) were 
developed with butanol : acetic acid : water (5 : 2 : 3) 
(HMG-CoA Rf = 0.2) and then visualized by 
autoradiography. Utrhzation of S-HMG-CoA 
could then be determined by assuming that R- 
HMG-CoA is non-metabolizable. This assumption 
was borne out by demonstrating that m standard 
HMG-CoA reductase assay mixes from CHO-Kl 
cells incubated with 14 PM R,S-HMG-CoA, 100% 
of the substrate could be accounted for by the 
recoverable mevalonolactone formed by the 
HMG-CoA reductase reaction and the total HMG- 
CoA counts recovered by thin-layer chromatogra- 
phy. It has been reported that only S-HMG-CoA 
can act as a substrate for HMG-CoA reductase 
[24]. In comparing MXl and CHO-Kl cell extracts 
for recovery of unreacted HMG-CoA, a sufficient 
amount of enzyme activity was used such that over 
a 30 min period an mmal concentration of 14pM 
R,S-HMG-CoA resulted m approx. 30% conver- 
sion of S-HMG-CoA to mevalonolactone through 
the HMG-CoA reductase catalyzed reaction. 
3. RESULTS AND DISCUSSION 
The mevmolin resistance of the MXl cell line 
isolated, as described in section 2, was compared 
by measurement of relative plating efficiency, to 
that of a Chinese hamster fibroblast line, CHL 
(AT-), and a somatic cell hybrid of MXl with this 
same mevmolm-sensitive line. The results (fig. 1) 
indicate that the MXl line is viable at mevmolm 
concentrations which can produce 100% krllmg of 
mevinolin-sensitive cells. Furthermore, a hybrid 
formed from the fusion of the MXl line with a 
mevmolin-sensitive Chinese hamster cell exhibits 
the same degree of mevinolm resistance as the 
resistant parent. Such a dominant resistance 
phenotype 1s consistent with an alteration m the 
HMG-CoA reductase of MXl, although rt IS also 
consistent with some other mechanisms of 
resistance (e.g., various detoxifying mechanisms). 
Since mevinolin is known to act as a competitor for 
the HMG-CoA binding site of HMG-CoA reduc- 
tase, we examined the substrate dependence of 
HMG-CoA reductase activity in crude extracts 
prepared from MXl and CHO-Kl cells to compare 
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Fig. 1 Survival of fibroblast hnes m various 
concentrations of mevmohn. Cells were inoculated at 
500 cells/35 mm petri dish m medium F12 supplemented 
with 8% neonatal calf serum and various concentrations 
of mevmohn The cultures were Incubated undisturbed 
for 7 days to form colonies and then the number of 
colonies formed determmed The number of colonies 
formed m the absence of mevmohn treatment was 
between 100 and 200 for each cell type tested (m) 
CHL (AT-), (~-4) MXl, ( M) MXI x CHL 
(AT-). 
the KIM for HMG-CoA and the KI for mevinolin in 
these two cell lines. These experiments (table 1) 
demonstrate that HMG-CoA reductase from MXl 
cells had a considerably lower KM for HMG-CoA 
than did the enzyme from wild-type cells and sur- 
prisingly had no observable alteration m the KI for 
mevmohn. The 6-fold lower KM for HMG-CoA 
observed m MXl accounts for most of the 
mevinohn resistance phenotype of these cells. 
Based on the relative rates of growth of MXl and 
CHO-Kl m various concentrations of mevmohn 
(flg.2), MXl is approx. 15-times more resistant o 
mevmohn than its CHO-Kl parental hne. We also 
noted (table 2) a 2-3-fold higher HMG-CoA syn- 
thase activity m MXl under these conditions (fetal 
calf serum supplements) which accounts for the re- 
Table 1 
Kmetlc parameters of HMG-CoA and mevmohn in 




KM 01M) KI (nM) 
7.2 f 1.5 1.3 * 04 
1.1 + 0.2 1.0 + 0.6 
4 6 8 10 12 14 16 18 20 
Mewnohn hg/ml) 
Flg.2 Growth of fibroblast hnes m various 
concentrations of mevmohn. Cells were maculated at 
2000 cells/35 mm petri dish m medium F12 
supplemented with 5% fetal calf serum and various 
concentrations of mevmohn The cultures were 
Incubated for 4 days and the cells harvested by 
trypsmlzatlon and counted with a Coulter counter. The 
data are expressed relative to untreated cultures 50% 
mhibltlon of growth IS observed at 0 35 pg/ml mevmohn 
m CHO-Kl (M) and 8 pg/ml m MXl (W) 
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Table 2 
Compartson of HMG-CoA synthase and reductase 
acttvttres m CHO-Kl and MXl 
Condtttons m culture 
CHO-Kl m FCS 
CHO-Kl m DIPE-2 




per mg) per mg) 
0 41 + 0 20 1.70 * 0 73 
1 72 f 0 19 7 12 + 0 48 
0 3 pg/ml 25-hydroxy- 
cholesterol 030*013 143*093 
MXl m FCS 1 09 + 0 04 1.58 + 0 15 
MXl m DIPE-2 3 06 + 0 53 7 97 + 0.55 
MXl m DIPE-2 + 
0 3 pg/ml 25hydroxy- 
cholesterol 0 78 + 0 04 0 42 k 0.08 
mainder of the resistance phenotype. Increased 
HMG-CoA synthase activity would confer mevi- 
nolin resistance by increasing intracellular levels of 
substrate for HMG-CoA reductase. 
The measurement of a different KM for HMG- 
CoA m the MXl cell hne 1s compromised by the 
performance of these determinations m crude cell 
extracts. It is conceivable that the lowered KM 
observed 1s actually due to differential utilization 
of HMG-CoA for other metabolic processes m 
these two cell types, and hence, is an artifact of a 
lowered catabolism of HMG-CoA by enzymatic 
reactions other than that catalyzed by HMG-CoA 
reductase. To examme this point, we developed a 
method for isolating unreacted HMG-CoA to 
determine the amount of total utthzatron of thts 
substrate in cell extracts. We found that under ap- 
propriate condrttons (see section 2) 100% of the S- 
HMG-CoA put mto the reaction mixture and not 
recovered as mevalonate was recoverable as HMG- 
CoA. This was the case for both the CHO-Kl 
parental cell hne and the MXl mutant. Hence, the 
possibrhty that the differential KM for HMG-CoA 
for these two cell types 1s due to differential 
catabolism of the substrate through alternate 
metabolic routes can be eliminated 
It should also be noted that a drop in the KM for 
HMG-CoA m the MXl line has the effect of mak- 
ing the HMG-CoA reductase of this cell more 
catalytrcally efficient. This observation of a 
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somatic cell mutation which apparently renders an 
enzyme better able to catalyze tts normal reaction 
is unusual. 
As described above, rt has been found that 
mutants with an altered level of HMG-CoA reduc- 
tase activity can be defective m the regulation of 
this enzyme. Furthermore, studies on mevmohn 
resistance m Chinese hamster ftbroblasts m other 
laboratories have shown that either overproduc- 
tion of HMG-CoA reductase [16,171 or a lack of 
recogmtron of serum cholesterol can produce a 
mevinolm resistant phenotype [25]. We thus 
measured the HMG-CoA reductase activity of 
MXl after mcubatron of the cells m dehprdrzed or 
sterol supplemented medium for 24 h. The ac- 
tivities found m CHO-Kl cells under comparable 
condttrons (without mevmolm treatment) are 
shown for compartson. The results (table 2) do not 
show any obvrous alteration m HMG-CoA reduc- 
tase expression m MXl relative to wild-type cells 
HMG-CoA synthase actrvity also appears to be 
regulated normally m these cells 
Taken together, the results presented here sug- 
gest that we have isolated a somatic cell mutant of 
the CHO-Kl cell designated MXl which has a 
mutation m the gene encoding HMG-CoA reduc- 
tase. This mutation confers resistance to mevmohn 
by virtue of an enhancement of the affinity of this 
enzyme for HMG-CoA 
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